Earnings Releases·Nov 5, 2026, 4:08 PM ET

Halozyme Therapeutics — Third Quarter 2026 Earnings Summary

Total revenue surged 39% year-over-year to $493.0 million, driven by a 44% increase in royalty revenue to $341.0 million, resulting in net income of $247.0 million and non-GAAP diluted EPS of $2.39.
Full-year 2026 guidance was raised across all key metrics: total revenue to $1.860–$1.925 billion, adjusted EBITDA to $1.240–$1.290 billion, and non-GAAP EPS to $8.75–$9.05, reflecting strong commercial momentum and new technology investments.
Strategic expansion included the advancement of three ENHANZE® programs to Phase 1, expanded collaborations with argenx, Incyte, and Janssen, and the FDA approval of TECENTRIQ HYBREZA® for a new indication.
Capital allocation activities included the issuance of $1.5 billion in convertible notes, $67.2 million in share repurchases (totaling $400 million for 2026), and a significant increase in cash and marketable securities to $1.08 billion.
Management highlighted a Dutch patent court victory against Merck Sharp & Dohme regarding Keytruda Qlex, while noting $7.5 million in litigation costs and increased R&D expenses due to recent acquisitions.